CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.
CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.
In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) a biotechnology company focused on developing psychedelic medicines to treat addiction.
In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound, DMT, to address the global addiction crisis, and how they are using genetics to develop more effective personalized treatment regimens for patients.
*To learn more about the company featured in this episode and the work they’re doing, visit their website: EntheonBiomedical.com
